C4 Therapeutics, Inc. - CCCC
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Apr 22, 2026 | SCHEDULE 13G/A | Wasatch Advisors LP | 4.7% | 4,581,761 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | OrbiMed Advisors LLC | 0.5% | 521,368 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | OrbiMed Capital LLC | 1.0% | 883,534 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Lynx1 Capital Management LP | 7.3% | 7,098,133 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Weston Nichols | 7.3% | 7,098,133 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Private Equity Fund III, L.P. | 5.9% | 6,072,822 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Private Equity GP III, LLC | 5.9% | 6,072,822 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus PE GP III, LLC | 5.9% | 6,072,822 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Capital Master Fund, L.P. | 9.99% | 10,361,860 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Capital, LLC | 9.99% | 10,361,860 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Capital Group, LLC | 9.99% | 10,361,860 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus Capital Management, L.P. | 9.99% | 10,334,114 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Soleus GP, LLC | 9.99% | 10,334,114 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Guy Levy | 9.99% | 10,334,114 | View |
| Feb 11, 2026 | SCHEDULE 13G/A | Morgan Stanley | 9.3% | 8,974,191 | View |
| Feb 11, 2026 | SCHEDULE 13G/A | Morgan Stanley & Co. LLC | 9.2% | 8,897,942 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | OrbiMed Advisors LLC | 2.3% | 1,666,800 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | OrbiMed Capital LLC | 5.0% | 3,568,346 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Wasatch Advisors LP | 6.8% | 4,852,741 | View |
| Oct 24, 2025 | SCHEDULE 13G | Bain Capital Life Sciences Fund II, L.P. | 1.07% | 991,188 | View |
| Oct 24, 2025 | SCHEDULE 13G | BCIP Life Sciences Associates, LP | 0.13% | 120,722 | View |
| Oct 24, 2025 | SCHEDULE 13G | BCLS II Equity Opportunities, LP | 6.25% | 6,060,000 | View |
| Oct 24, 2025 | SCHEDULE 13G | RA Capital Management, L.P. | 9.9% | 9,441,256 | View |
| Oct 24, 2025 | SCHEDULE 13G | Peter Kolchinsky | 9.9% | 9,441,256 | View |
| Oct 24, 2025 | SCHEDULE 13G | Rajeev Shah | 9.9% | 9,441,256 | View |
| Oct 24, 2025 | SCHEDULE 13G | RA Capital Healthcare Fund, L.P. | 9.9% | 9,441,256 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.